Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (‘CNS’) disorders,…
Investing
Locksley Announces Major Advancement at Mojave as Structural Mapping Expands Scale of Antimony Target with a 400% Increase in Target Strike Length
Locksley Resources, Ltd. (ASX: LKY,OTC:LKYRF; OTCQX: LKYRYF) announced that recent structural mapping has significantly expanded the scale of its…